Imuran (Azathioprine)

Azathioprine is converted in the body to 6‑mercaptopurine, which blocks the synthesis of purine nucleotides needed for DNA and RNA production. This inhibition limits the proliferation of T and B lymphocytes, reducing immune cell activation and providing broad immunosuppression.

The appropriate dose of Imuran is individualized by the prescribing clinician based on the specific condition, patient weight, renal and hepatic function, and laboratory monitoring results. Dosage adjustments are made to achieve therapeutic effect while minimizing toxicity.

Imuran is classified as Pregnancy Category D, indicating evidence of fetal risk. It should only be used during pregnancy if the potential benefit justifies the risk. Limited data are available for breastfeeding; the drug may pass into breast milk, so a healthcare professional should evaluate safety before use.

To request Imuran, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with alternatives such as mycophenolate mofetil or methotrexate, azathioprine offers a well‑established efficacy profile for transplant prophylaxis and several autoimmune diseases. Its side‑effect spectrum differs, with a higher risk of bone‑marrow suppression but lower incidence of gastrointestinal toxicity seen with some other agents.

Imuran tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and avoid storing in bathrooms or other humid environments.

Imuran is taken orally as a tablet, usually with food or a glass of water to reduce gastrointestinal irritation. The exact timing and whether it should be taken with meals are determined by the prescribing physician based on individual tolerance and treatment plan.

The most serious risks include severe bone‑marrow suppression leading to anemia, leukopenia or thrombocytopenia; liver toxicity; pancreatitis; increased susceptibility to opportunistic infections; and a potential heightened risk of certain malignancies such as lymphoma. Regular laboratory monitoring is essential.

Imuran is contraindicated in patients with known hypersensitivity to azathioprine or its metabolites, those who are pregnant unless benefits outweigh risks, individuals with active severe infections, and patients with significant hepatic impairment. It should also be used with caution in the elderly and in those with pre‑existing bone‑marrow disorders.